• News
    • News
    • Upcoming Events
    • Subscribe
  • Our Company
    • Our Story
    • Our Vision
    • Board of Directors
    • Alzinova Team
    • Advisers & Collaborators
  • Patients & Families
    • Alzheimer's Patients
    • Impact on Society
    • The Unmet Medical Need
  • R & D
    • Alzheimer's Disease
    • Our Programs
    • Specific Targeting of Toxic Aβ Oligomers
    • The AβCC Peptide™ Technology
    • Scientific Presentations
  • Investors
    • Overview
    • News
    • Analyses
    • Press Releases
      • English
      • Swedish
      • Subscribe
    • Presentations
    • Board and Management
    • The Share
    • Financial Reports
      • Financial Reports - English
      • Financial Reports – Swedish
      • Financial Calendar
    • Corporate Governance
    • General Meetings
    • IR Contact
  • Career
  • Contact
logo
  • News
    • News
    • Upcoming Events
    • Subscribe
  • Our Company
    • Our Story
    • Our Vision
    • Board of Directors
    • Alzinova Team
    • Advisers & Collaborators
  • Patients & Families
    • Alzheimer's Patients
    • Impact on Society
    • The Unmet Medical Need
  • R & D
    • Alzheimer's Disease
    • Our Programs
    • Specific Targeting of Toxic Aβ Oligomers
    • The AβCC Peptide™ Technology
    • Scientific Presentations
  • Investors
    • Overview
    • News
    • Analyses
    • Press Releases
      • English
      • Swedish
      • Subscribe
    • Presentations
    • Board and Management
    • The Share
    • Financial Reports
      • Financial Reports - English
      • Financial Reports – Swedish
      • Financial Calendar
    • Corporate Governance
    • General Meetings
    • IR Contact
  • Career
  • Contact
Home / Investors / The Share
  • Overview
  • News
  • Analyses
  • Press Releases
    • English
    • Swedish
    • Subscribe
  • Presentations
  • Board and Management
  • The Share
  • Financial Reports
    • Financial Reports - English
    • Financial Reports – Swedish
    • Financial Calendar
  • Corporate Governance
  • General Meetings
  • IR Contact

The Share

Share Information

The Alzinova share is traded on Nasdaq First North Growth Market. The company has a registered share capital of 27,437,103.98 SEK, divided on 104,323,588 shares. The quota value is 0.263 SEK/share. Shares are registered by Euroclear Sweden AB.

Name: Alzinova AB
Ticker: ALZ
ISIN code: SE0007413455
LEI-code: 549300K3IMVT20EK2S13

Share price and trading can be followed on Nasdaq First North Growth Market 

Liquidity provider Mangold Fondkommission acts as liquidity provider for the Alzinova share. The purpose is to promote liquidity in the trading of the share. The agreement and the trading of the liquidity provider started July 1, 2024.

Largest Shareholders

As per Euroclear, 30 June 2025

Largest Shareholders

Certified Adviser

Alzinova AB has contracted Mangold Fondkommission AB as Certified Adviser on Nasdaq First North Growth Market. As a Certified Adviser, Mangold guide and monitor the company’s compliance on Nasdaq First North Growth Market.

Contact information to Mangold Fondkommission AB:
Info@mangold.se
phone +46 (0)8-503 01 550

Rights issues & Share capital development

Previous Share Issuances

Share Capital Development

  • News
  • Our Company
  • Patients & Families
  • R & D
  • Investors
  • Contact

Alzinova AB, Gemenskapens gata 9,  SE-431 53 Mölndal
info@alzinova.com

Follow us on

follow us on linkedin